STOCK PURCHASE AGREEMENTStock Purchase Agreement • March 16th, 2015 • Agenus Inc • Biological products, (no disgnostic substances) • Delaware
This Stock Purchase Agreement (this “Agreement”) is dated as of January 9, 2015, between Agenus Inc., a Delaware corporation (the “Company”), and Incyte Corporation, a Delaware corporation (the “Purchaser”).
LICENSE AGREEMENTLicense Agreement • March 16th, 2015 • Agenus Inc • Biological products, (no disgnostic substances) • New York
This License Agreement (this “Agreement”), dated as of December 5, 2014 (the “Effective Date”), is made by and between 4-Antibody AG, a limited liability company organized under the laws of Switzerland with an office at Hochbergerstrasse 60C, CH-4057 Basel, Switzerland (“4-AB”), and the Ludwig Institute for Cancer Research Ltd., a non-profit corporation organized under the laws of Switzerland with its registered office at Stadelhoferstrasse 22, 8001 Zurich, Switzerland and an office at 666 Third Avenue, New York, New York 10017, USA (“LICR”). Each of 4-AB and LICR may be referred to in this Agreement individually as a “Party” and, collectively, as the “Parties”.
LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BY AND BETWEEN AGENUS INC., 4-ANTIBODY AG, INCYTE EUROPE SARL, AND INCYTE CORPORATION, SOLELY FOR PURPOSES OF SECTION 12.16Development and Commercialization Agreement • March 16th, 2015 • Agenus Inc • Biological products, (no disgnostic substances)
THIS LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the “Agreement”) is entered into as of January 9, 2015 (the “Execution Date”) by and between Agenus Inc., a Delaware corporation having its principal office at 3 Forbes Road, Lexington, Massachusetts 02421, USA (“Agenus US”) and its wholly-owned subsidiary, 4-Antibody AG, a stock corporation organized under the laws of Switzerland with an office at Hochbergerstrasse 60C, CH-4057, Basel, Switzerland (“4-AB” and, together with Agenus US other than with respect to Section 12.17(s), “Agenus”), and Incyte Europe Sarl, a Swiss limited liability company (a société à responsabilité limitée) having its principal office at Cours de Rive 13, 1204, Geneva, Switzerland (“Incyte”) and solely for purposes of Section 12.16, Incyte Corporation, a Delaware corporation having its principal office at 1801 Augustine Cut-off, Wilmington, Delaware 19803 USA (“Parent”). Agenus and Incyte may be referred to in this Agreement individually as a “Party” a
